Stocks · News reference
Valneva (NASDAQ:VALN) affirms FY2026 sales outlook from $169.795 million-$187.360 million to $169.795 million-$187.360 million vs $171.630 million estimate.
Reference details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Benzinga readers can review the latest analyst takes on high-yielding stocks in health care sector. Top analysts & recent news on PRGO, PFE, BMY.
Read original at benzingaStock futures mixed, Nasdaq 100 down 100 points. Applied Optoelectronics falls after announcing $600M offering. Other pre-market losers include RFAI, ZSTK, ZKH, JMIA, VALN, MFI, COHR, SNDK, AXTI, ASTL, LITE, STX.
Read original at benzingaValneva (VALN) stock surges after EMA validates MAA for Lyme disease vaccine candidate developed with Pfizer (PFE). Phase 3 trial showed efficacy and no safety concerns, pending regulatory approval.
Read original at benzingaDow falls 0.26% while Nasdaq drops 0.51%. Energy shares rise 1.3%, tech stocks fall 0.6%. US retail sales down 0.6%, consumer sentiment declines.
Read original at benzinga